Legal attitude: Art. 17 para. 1 MAR - confidential information.
MedApp SA Management Board with its registered office in Kraków ("the Company", "Issuer") informs that the Company has signed a letter of intent with the company Future Processing Sp. z o.o. with headquarters in Gliwice.
The parties to the letter of intent declared willingness to establish cooperation (within the development of the CarnaLife telemedical platform belonging to the Issuer) in the field of data simulation solutions and 3D and 4D imaging in the field of oncology and cardiology.
Future Processing Sp. z o.o. is an IT company that produces specialized computer software for international trade, industry and services. Future Processing engineers created software to support the diagnosis of neoplastic changes in the brain. Future Processing experts have also worked on advanced systems for fluoroscopy, angiography, cancer diagnostics and statistical analysis of medical images for the British company Cambridge Computed Imaging Ltd. (CCI).
The Issuer expects that establishing cooperation with Future Processing will facilitate the sale of the CarnaLife system in the healthcare sector.
The Issuer informs that the nature of the letter of intent is not binding, which means that the terms of cooperation will be determined under a separate agreement. The Company will immediately inform about its conclusion or withdrawal from the implementation of the intentions of this letter of intent.
Source: company website, investor relations, current and periodic reports.